Oncolytics Biotech Inc
TSX:ONC

Watchlist Manager
Oncolytics Biotech Inc Logo
Oncolytics Biotech Inc
TSX:ONC
Watchlist
Price: 1.73 CAD -2.81% Market Closed
Market Cap: 153.7m CAD

Relative Value

There is not enough data to reliably calculate the relative value of ONC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ONC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.6
vs History
vs Industry
Median 3Y
-4.2
Median 5Y
-4.3
Industry
24.2
Forward
-4.2
vs History
vs Industry
7
Median 3Y
-4.2
Median 5Y
-5
Industry
20.3
vs History
vs Industry
5
Median 3Y
-4.2
Median 5Y
-4.9
Industry
22.9
vs History
0
vs Industry
7
Median 3Y
5.6
Median 5Y
5.1
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
7.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
10
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-3
Industry
5.1
Forward
-2.1
vs History
vs Industry
Median 3Y
-2.5
Median 5Y
-2.9
Industry
5.1
Forward
-3.1
vs History
vs Industry
8
Median 3Y
-3
Median 5Y
-3.4
Industry
5.7
vs History
vs Industry
7
Median 3Y
-3
Median 5Y
-3.4
Industry
4.2
vs History
22
vs Industry
14
Median 3Y
25.5
Median 5Y
30.9
Industry
5.2

Multiples Across Competitors

ONC Competitors Multiples
Oncolytics Biotech Inc Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
Oncolytics Biotech Inc
TSX:ONC
149.5m CAD 0 -4.7 -4.1 -4
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 159 077.2 -162 353 -197 148.4 -194 898.7
US
Abbvie Inc
NYSE:ABBV
334.3B USD 5.8 80.5 15.3 22.6
US
Amgen Inc
NASDAQ:AMGN
158.5B USD 4.6 26.7 14.4 23.7
US
Gilead Sciences Inc
NASDAQ:GILD
134.7B USD 4.7 22.6 9.8 13.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
118.2B USD 10.6 -119.5 25.4 26.6
US
Epizyme Inc
F:EPE
94.1B EUR 2 062.4 -526.3 -573.1 -557.8
AU
CSL Ltd
ASX:CSL
124.6B AUD 5.3 29.5 18.1 22.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
58.7B USD 4.2 13 11.6 13.1
US
Seagen Inc
F:SGT
39.3B EUR 19.9 -60.9 -65.7 -59.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD 17.8 -154.9 -694.7 -348.1
P/S Multiple
Revenue Growth P/S to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/S: 3 416 121.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 159 077.2
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
8%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.6
4%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.7
3%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10.6
10%
1.1
US
E
Epizyme Inc
F:EPE
2 062.4
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
4%
1
US
S
Seagen Inc
F:SGT
19.9
30%
0.7
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.8
30%
0.6
P/E Multiple
Earnings Growth PEG
CA
Oncolytics Biotech Inc
TSX:ONC
Average P/E: 34.5
Negative Multiple: -4.7
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -162 353 N/A N/A
US
Abbvie Inc
NYSE:ABBV
80.5
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.7
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
22.6
189%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -119.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -526.3 N/A N/A
AU
CSL Ltd
ASX:CSL
29.5
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -60.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -154.9 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBITDA: 15.8
Negative Multiple: -4.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -197 148.4 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.3
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
9.8
6%
1.6
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.4
17%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -573.1 N/A N/A
AU
CSL Ltd
ASX:CSL
18.1
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.6
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -65.7 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -694.7 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CA
Oncolytics Biotech Inc
TSX:ONC
Average EV/EBIT: 20.4
Negative Multiple: -4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 898.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.6
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.7
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
13.6
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.6
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -557.8 N/A N/A
AU
CSL Ltd
ASX:CSL
22.7
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.1
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -348.1 N/A N/A